logo
  

Toyota Motor Q1 Profit, Vehicle Sales Down; Lifts FY23 View; Stock Down - Quick Facts

Toyota Motor Corp. (TYT.L,TM), a Japanese automotive major, reported Thursday that its first-quarter net income attributable to the company fell 18 percent to 736.82 billion yen or 53.65 yen per share from last year's 897.83 billion Yen or 64.23 Yen per share last year.

Operating income amounted to 578.66 billion Yen, down 42 percent from the previous year's 997.49 billion Yen.

Sales revenues for the period increased 7 percent to 8.49 trillion Yen from 7.94 trillion Yen generated in the prior year period.

Vehicle sales for the period declined to 2.01 million units from 2.15 million units last year.

Looking ahead for fiscal 2023, the company now expects attributable profit of 2.36 trillion yen or 171.95 yen per share, down 17.2 percent from last year; operating income of 2.40 trillion yen, down 20 percent from last year, and sales revenues of 34.50 trillion yen, up 10 percent from the prior year.

The company previously expected profit of 2.260 trillion yen and sales revenues of 33 trillion yen.

In Japan, Toyota Motor shares were trading at 2,094.50 yen, down 2.85 percent.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Consumer Product Safety Commission or CPSC announced recall of thousands of children's Robes made in China and sold exclusively on Amazon.com by various companies. The recalled robes fail to meet the federal flammability standards for children's sleepwear, posing a risk of burn injuries to children. Further, citing the same concerns, Paper Cape children's pajamas manufactured in Peru ... Health services company Cigna Corp. reported Friday higher profit in its fourth quarter reflecting growth in both Evernorth and Cigna Healthcare segments. Adjusted earnings and topline beat market estimates. Looking ahead for fiscal 2023, the company projects adjusted earnings and adjusted revenues to be higher than last year, but below market view. French drug major Sanofi SA reported Friday higher profit in its fourth quarter with strong revenue growth mainly with strong sales of Dupixent. Looking ahead for fiscal 2023, the company projects higher business earnings, but the expected growth is slower than recorded in fiscal 2022. Sanofi shares were losing around 4 percent in the morning trading in Paris as well as in pre-market activity...
Follow RTT